Lord, Abbett & Co
EDIT icon

Lord, Abbett & Co’s Editas Medicine EDIT Stock Holding History

Lord, Abbett & Co’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-707,398
Closed -$29.1M – 635
2021
Q3 		$29.1M Buy
+707,398
New +$38.8M 0.07% 360

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Lord, Abbett & Co's EDIT Position: Q4 2021 in Review

Lord, Abbett & Co sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 707,398 shares — an estimated $29.1M sold.

Lord, Abbett & Co first reported a position in EDIT in Q3 2021 and held it in 1 quarter. The position peaked at $29.1M in Q3 2021. 305 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

  • Lord, Abbett & Co reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 707,398 Editas Medicine shares in Q4 2021, an estimated $29.1M.
  • Lord, Abbett & Co first reported a position in Editas Medicine in Q3 2021 and held it in 1 quarter.
  • Lord, Abbett & Co's Editas Medicine position peaked at $29.1M in Q3 2021.
  • 305 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on Lord, Abbett & Co's 13F filing for Q4 2021, filed 11 Feb 2022.